All News

The highest cumulative 120-day rates of ED visits and HA were observed in patients who underwent percutaneous nephrolithotomy procedures.

"UH is working on starting clinics throughout rural Northeast Ohio, and we're meeting to develop a FPMRS program, both virtual and in-person, so patients can have access to this point of care," says David Sheyn, MD.

“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.

“Now in 2023, it’s really a question of how to apply these agents and which combinations to use in the first line,” said Vincent (Wenxin) Xu, MD.

The enzalutamide/leuprolide combo also led to statistically significant improvements in time to PSA progression and time to start of new antineoplastic therapy.

Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.

“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.

“What is precision medicine? This is not just a vague term; it really looks at individual characteristics of a patient to decide treatment," said Leonard G. Gomella, MD, FACS.

“The more we can use AI to streamline all the less attractive aspects of our job, the better,” says David Canes, MD.

"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.

The investigators used data from the National Inpatient Sample database to identify 5280 patients with non-metastatic bladder cancer who underwent RC from 2016 to 2019.

"While past global studies have supported the use of Xtandi plus ADT in men with mHSPC, it is encouraging to see these results replicated for patients in mainland China," said Zhou Fangjian, MD.

"We think this is an important call to action for the NCCN to follow in the footsteps of the AUA, who recently removed VLR from its prostate cancer guidelines in its most recent update," says Kevin Shee, MD, PhD.

“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.

Urologists should watch early adopters of MVPs to know what to expect.

"Our recommendation is to adopt a Mediterranean diet enlisting the help of a dietician, because people absorb nutrients in different ways, depending on the food, the digestive system, the person’s genotype and possibly their microbiome," says Permal Deo, MD.

"Increasing regulation, excess bureaucracy, decreasing autonomy, declining reimbursement, and increased administrative burdens are all increasing the risk of burnout," says Andrew M. Harris, MD.

"The pendulum is swinging back. It’s all about provider education, hammering home the point that we have to do appropriate screening," says urologist Ryan Hankins, MD.

An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Treatment with nivolumab in patients with high-risk muscle-invasive urothelial carcinoma continued to improve survival, supporting its use as a standard of following radical resection.

In cohort B of the phase 2 Keynote-057 trial, pembrolizumab led to antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.

Treatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.

The ORR for patients was 47%. Of note, ORRs were higher in patients with specific alterations compared with wild type including ERBB2 (67% vs. 44%, respectively; P = .05) and TSC1 (68% vs. 25%; P = .04).

The combination use of niraparib plus abiraterone and prednisone continued to improve outcomes in patients with metastatic, castration-resistant prostate cancer and HRR gene alterations.

In the the phase 2 HCRN GU 16-257 trial, 33 patients with muscle-invasive bladder cancer were eligible to forego cystectomy and continue 240-mg maintenance nivolumab monotherapy every 2 weeks for 8 cycles followed by surveillance.

Key benefit to expansion of telehealth lies in expanded access.

Nearly three-fourths of physicians doing contract work reported experiencing little to no burnout.

“A majority of patients that present with bladder cancer do not have muscle invasive disease. They have earlier stage, non-muscle invasive, and the NCCN guidelines have detailed guidance for providers about managing those patients,” said Thomas Flaig, MD.